• Netarsudil meets IOP-lowering endpoint in phase 3 trial in Japan

    5 days ago - By Healio

    Netarsudil 0.02% appears to be more effective at lowering IOP in patients with open-angle glaucoma or ocular hypertension than ripasudil 0.4% in a phase 3 clinical trial, according to a press release from Aerie Pharmaceuticals.
    “We are pleased to have successfully completed our first phase 3 clinical trial in Japan which further confirmed that netarsudil ophthalmic solution 0.02% achieves impressive IOP-lowering efficacy in a patient population with lower baseline pressures,” Benjamin F. McGraw III, PharmD, interim executive chairman at Aerie, said in the release.
    The randomized,
    Read more ...

     

  • Can Phase 3 Data Really Guide Clinical Decision-Making?

    Can Phase 3 Data Really Guide Clinical Decision-Making?

    5 days ago - By Medscape

    Oncologist Jack West explores the limits of phase 3 data to provide clear treatment options for the many subgroups of patients.
    Medscape Oncology
    Read more ...